-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Avalo Therapeutics, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2015 to 2023.
- Avalo Therapeutics, Inc. Income Tax Expense (Benefit) for the quarter ending June 30, 2024 was $7K, unchanged year-over-year.
- Avalo Therapeutics, Inc. Income Tax Expense (Benefit) for the twelve months ending June 30, 2024 was $13K, a 55.2% decline year-over-year.
- Avalo Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2023 was $14K, a 50% decline from 2022.
- Avalo Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2022 was $28K.
- Avalo Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2021 was -$196K, a 93% increase from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)